Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tipifarnib (Janssen Pharmaceutica).

Peter Norman1

  • 1Norman Consulting, Burnham, Bucks, UK. peter.norman2@btinternet.com

Current Opinion in Investigational Drugs (London, England : 2000)
|May 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The lived experience of depression: a bottom-up review co-written by experts by experience and academics.

World psychiatry : official journal of the World Psychiatric Association (WPA)·2023
Same author

Brexit and UK market exclusivities.

Pharmaceutical patent analyst·2018
Same author

Humira<sup>®</sup>: recent developments.

Pharmaceutical patent analyst·2017
Same author

Enbrel and etanercept biosimilars: a tale of two patent systems.

Pharmaceutical patent analyst·2017
Same author

Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.

Expert opinion on investigational drugs·2016
Same author

Humira: the impending patent battles over adalimumab biosimilars.

Pharmaceutical patent analyst·2016
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Tipifarnib, a RAS farnesylation inhibitor, is under development for treating various cancers. Clinical trials are underway for non-small cell lung cancer, pancreatic cancer, and leukemia.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Janssen is developing tipifarnib (formerly R-1 15777), a RAS farnesylation inhibitor.
  • This drug is being investigated for the potential treatment of various neoplastic diseases.

Purpose of the Study:

  • To evaluate the efficacy and safety of tipifarnib in patients with different types of cancer.
  • To advance tipifarnib through clinical trial phases for potential therapeutic applications.

Main Methods:

  • Initiation of clinical trials in the US in April 1997, in collaboration with the National Cancer Institute.
  • Progression through Phase II and Phase III clinical trials for advanced non-small cell lung cancer, pancreatic cancer, leukemia, and RAS-dependent solid tumors.

Main Results:

  • Phase II trials were planned for advanced non-small cell lung cancer by May 1999.

Related Experiment Videos

  • Phase III trials for pancreatic cancer and leukemia were initiated by February 2001.
  • Tipifarnib was in Phase II trials for RAS-dependent solid tumors by June 2001.

    • Conclusions:

    • Clinical development of tipifarnib is progressing across multiple cancer types.
    • Regulatory filings and US market introductions were projected for 2002-2005 for pancreatic cancer and other malignancies.